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Unlike medications, the dissemination of surgical procedures into practice is not regulated.
Before marketing, pharmaceutical products are required to be shown safe and efficacious in
comparative clinical trials which utilize bias-reducing strategies designed to reduce the
distortion of estimates of treatment effect by predispositions towards the investigational
intervention or control. Unless an investigational device is involved, the corresponding
process for surgical innovations is usually unregulated and therefore may not be based upon
adequate evidence. Given these differences, we sought to evaluate the state of clinical
research on invasive procedures.
We conducted a systematic review of publications from 1999–2008 that reported the results
of studies evaluating the effects of invasive therapeutic procedures, focusing on trials which
appeared to influence practice. Our objective was to determine what proportion of studies
evaluating surgical procedures use a comparative clinical trial design and methods to control
bias. This paper reports our results and raises concerns about the methodological, and
therefore the ethical, quality of clinical research used to justify the implementation of
surgical procedures into practice.
Methods
After reviewing the National Library of Medicine’s list of medical subject headings and
eliminating those for which surgery is not a viable treatment option, 36 non-rare medical
conditions were identified for which a surgical treatment modality exists. We systematically
searched these headings (subsequently consolidated to 33) for comparative clinical trials
investigating the effectiveness of a surgical or minimally invasive procedure. Studies from a
broad range of specialties were sought.
We conducted an electronic search of MEDLINE from January 1999 through December
2008 for English-language reports of comparative clinical trials of invasive therapeutic
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procedures using a modified version of the Cochrane Highly Sensitive Search Strategy
(HSSS).1 Search terms were tested at each stage of an iterative revision of the HSSS by
reviewing a random sampling of the results of a test search for precision and sensitivity. See
Table 1 for the final search algorithm used. Bibliographies of metaanalyses retrieved by the
search were hand-reviewed for potential eligible studies.
All search results were reviewed for eligibility separately by one of four research assistants
and one of two investigators (DMW or CMA) via a stepwise process. Studies were
eliminated based on title, abstract, or a full review of the article text. Studies were excluded
which evaluated perioperative adjuncts (medications, types of anesthesia, etc.) or minor
technical elements of surgical procedures. Inclusion criteria were minimal and required at
least two study arms (comparative trial), ≥ 30 participants, a description of allocation
method within the report, and trial endpoints with discernible clinical significance to the
participant. Disagreements regarding inclusion were resolved through discussion.
We tried to identify those trials which have had the greatest impact on clinical practice using
an original unvalidated measure based on citation analysis of trial reports. Citation searches
were conducted for each publication using the Web of Science database2 to identify
scholarly citations, and the news search function of the LexisNexis database3 to identify
citations in mainstream news sources. Within each subject heading, the five reports with the
most citations per year since publication were included in the review pool. For any heading
with ≤5 eligible reports, all were included (Influence Criterion 1). For reports published
within the last two years of the inclusion period, those which had ≥10 citations per year in
the LexisNexis search were included (Influence Criterion 2), to correct for any bias in
selection arising from temporal constraints of research dissemination and to retrieve trials
most representative of current levels of rigor. Neither journal quality nor impact factor were
explicitly taken into account by the influence criteria, although it is probable that such
factors informed the results as studies published in higher-impact journals are likely to have
been cited more frequently. Any report which met either influence criterion was included in
our final pool for review.
A standardized review was then conducted on each eligible report that met influence criteria
to capture key descriptive elements of the trial and to collect information on attributes
known to bolster internal validity – the confidence with which we can draw a conclusion
about the difference between treatments based on study results – and those needed to assess
the generalizability of study results, or external validity.4 Responses were limited to yes/no,
true/false, and multiple choice elements in order to limit variability and ensure consistency
across reviewers. Practice reviews were conducted by all six investigators on reports of
ineligible trials to assess and correct any problems with inter-rater reliability. Subsequently,
each individual trial was reviewed and evaluated by one investigator. Ambiguous or unclear
cases were brought before the entire team for review and consensus resolution.
Results
The search yielded 37,944 unique articles across 33 medical subject headings. 2,890 trials
(7.6%) met our inclusion criteria (Table 2). Of the 37,944 unique records, 166 were meta-
analyses and 175 were unique reports identified via review of those meta-analyses.
Proportions of eligible trials by medical subject heading varied from <0.5% (Carcinoma,
Ductal, Breast) to 23.5% (Prostatic Hyperplasia). Application of influence criteria identified
290 trials for review (Table 2). Trials of cardiovascular procedures accounted for 18.3%
(n=53) of the pool while trials of neurological procedures represented only 4.8% (n=14). See
Figures 1 and 2 for sample flow charts of trial inclusion and exclusion.
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After a full review of the reports, we evaluated the hypothesis that those studies identified
by the two different influence criteria would not vary by fidelity to reporting and design
standards. A Chi Square test employing the Bonferroni method for adjustment for multiple
comparisons showed no significant difference between the two samples on 68 of 70
variables. Data are therefore presented in summary form for all studies surveyed. No other
subgroup analyses were conducted.
Of trials surveyed, more than a third (104/290, 35.9%) did not identify the trial sponsor. Of
186 reporting sponsorship, 32.3% (60) were solely commercially funded, and another 15.6%
(29) were had joint commercial and non-commercial funding. Included reports were roughly
equally divided between device trials (142/290, 49%) and non-device trials (148/290, 51%).
Of 95 device trials reporting sponsorship, 64 (67.4%) had some level of commercial
sponsorship.
A significant number of reports failed to disclose basic information necessary to assess the
internal validity of results. A formal statistical power calculation was reported in only two-
thirds (63.4%; 184/290), and of these 13% (24) failed to include one or more elements of a
complete power calculation: estimated treatment outcomes for each group, standard
deviation for continuous variables, the alpha or significance level (Type 1 error), and the
beta (Type 2 error) level or, conversely, power. Fewer than half of reports (42.4%, 78/184)
made explicit allowance for attrition in the power calculation.
15.5% (45/290) failed to specify the primary endpoint used in analysis. Out of 245
specifying an endpoint, 14.3% (35) used a composite endpoint and 20.8% (51) used a
subjective endpoint. Fewer than half of trials utilizing subjective endpoints (47.1%) reported
the provenance (origin) of the subjective scale, and 2% (1), 3.9% (2), and 0% provided data
to support the validity, reliability, and sensitivity of the scale, respectively.
Thirty of 290 trials (10.3%) used deterministic allocation schemes, while less than half of
randomized trials reported the method of allocations sequence generation (41%, 105/256).
Most studies did not report the use of blinding (60.7%; 176/290), and only 46 trials (40.4%
of trials reporting blinding, 15.9% of total sample) reported blinding the primary outcome
assessor. Only 20 out of 51 trials using subjective endpoints reported blinding of the primary
outcome assessor (39.2%). Additional data regarding features affecting the internal validity
of the trials surveyed can be found in Table 3.
Half of studies specifying the number of trial sites were single-center (133/266). The median
number of sites in multi-center studies was 12 (range 2–217). 88% of multicenter trials
(117/133) failed to identify any eligibility criteria for inclusion of a center. Of the few
reports that disclosed the number of participating interventionists (65/290), roughly half
(34/65) had multiple, with a median of 3.5 (range 2–66). Only 14/34 multi-interventionist
trials specified eligibility criteria for interventionist participation (41.2%).
Of the 89 trials reporting some commercial sponsorship, 29.2% (26) reported the sponsor’s
role in the design of the trial, 34.8% (31) in data analysis, and 32.6% (29) in the preparation
of the manuscript. Other trial features affecting the generalizability of trial results can be
found in Table 4.
Discussion
This study assessed the proportion of published evaluations of invasive therapeutic
procedures that used a comparative clinical trial design, and the methodological quality of
the most influential of those trials. We note three main findings. First, a very low proportion
of studies evaluating surgical procedures met the minimal design attributes we specified as
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inclusion criteria – 7.6% overall. This may indicate the acceptance on face validity of
practices which have not been adequately tested, or may be a reflection of the many barriers
to conducting well-designed comparative trials of surgical procedures, such as the relatively
high cost associated and correspondingly limited funding for nondevice surgical trials, or
difficulties recruiting patients to randomized trials of operations.5, 6
Second, despite focusing on comparative trials, our review uncovered deficient reporting of
important aspects of clinical trials, such as funding source (36% failure), complete statistical
power calculations (45% failure), and factors required to assess the generalizability of trial
results, e.g., the number and inclusion criteria of interventionists (78% and 59% failure,
respectively) and centers (8% and 88% failure, respectively).
Third, we found that while some bias-reducing strategies were frequently used (such as
randomization), others were often forgone. Blinding was reported in only four of ten trials
overall, and in trials using subjective endpoints, where blinding is key to unbiased
assessments, six of ten trials did not blind the primary outcome assessor.
There is international consensus that scientifically unsound trials are ipso facto ethically
problematic, because they do not produce generalizable knowledge sufficient to justify the
use of human participants.7, 8 In light of this, our findings indicate failures on the part of
investigators, independent review boards, and peer reviewers. Such failures suggest that
highly motivated trialists and reviewers may nevertheless be inadequately trained to ensure
the use of the best scientific methods in clinical research. In a previous work, we have
documented both that the standards governing the conduct of clinical trials are numerous, as
well as the inherent difficulty in locating, assimilating, and applying such standards.9 These
factors may present a real barrier to the ethical conduct of surgical trials, and as such may
indicate the need for greater attention to the institutional structure(s) in which surgical
research is developed, reviewed, and conducted.
The dissemination of surgical innovations in advance of evidence of effectiveness from
randomized trials has long been a matter of concern.10 Our study provides the best estimate
yet of how often such procedures are evaluated in comparative trials generally, as well as
with randomized controlled trials implementing bias-reducing strategies. With some
exceptions,11–13 previous studies counted only the number of studies or clinical trials in
major surgical journals,14–17 or in one case identified only studies published in general
medical journals.18 Most did not distinguish between trials evaluating surgical procedures
and those evaluating surgical adjuncts or drugs related to surgical procedures.15 In contrast,
we examined trials across journal types, and differentiated between comparative studies and
case series. Our approach enabled us to identify a sizeable number of prospective
comparative trials of invasive therapeutic procedures which could indicate the current state
of the art of research into invasive medicine. Because we identified those studies most
widely cited within the literature, our analysis focused on those trials most likely to be
impacting current clinical practice.
The practical implications of these findings are at least threefold. First, these findings
suggest that more emphasis on applying the CONSORT requirements to nonpharmaceutical
treatment modalities4 could vastly improve the evidence available to surgical
interventionists. If pressure was consistently exerted by journal editors and peer reviewers,
fidelity to reporting criteria would likely increase.
Second, improvement in clinical research training in the surgical sub-specialties is
necessary, as is the establishment of stronger research infrastructure for surgeons.19
Although some research institutions have begun to incorporate research fellowships into
their surgical training, such practices have yet to become mainstream. Additional progress
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can be made in the education and training of independent review board members, who must
approve surgical research programs before they are implemented.
Finally, although there are unique hurdles to surgical clinical trials,20–24 our findings
suggest that scientific rigor is not always prohibitively demanding. Almost 90% of reviewed
studies did randomize participants, suggesting that the barriers to successful randomization
may not be as large as is often presumed. Our results also suggest that blinding the
participant in surgical research is achievable,15 at least when surgical procedures are tested
against other invasive interventions. Methods of using blinding in surgical trials have been
suggested in the literature,25 and regardless of the nature of the comparator, there is often no
substantial obstacle to blinding independent outcome assessors,26 a practice which we saw
in only 16% of our full sample. Something as simple as blinding outcome assessors can do a
great deal to limit biases in estimates of treatment effects.
There are at least three limitations to our results. First, we evaluated the published reports of
trials, which are significantly limited by the length restrictions of most medical journals.
Therefore, it is unclear what amounts of the failures we identify reflect mere reporting
deficiencies and what proportion indicate a lack of methodological rigor in our sample.
However, reporting failures are also a concern, as deficits in methods reporting are
correlated with inflated estimates of treatment effects,27 and interventionists must be able to
evaluate a procedure on the basis of the published reports.
Second, our analysis did not evaluate whether there was general improvement in the quality
of surgical trials over the period of review. This is an important question which we were
unable to address due both to a limited sample size and the manner in which our data was
coded, which did not easily convert into a summary quality metric. The extension of the
CONSORT statement to non-pharmacological treatment modalities, as well as the growing
attention paid to research methodology in the surgical literature have hopefully had a
positive impact on the quality of surgical trials over recent years.4
Finally, our study utilized an unverified measure of influence to reduce the size of our
sample. This method assumes both that the publication of research results has a direct causal
impact on clinical practice, as well as that the citation rate of trial reports is an appropriate
surrogate for a trial’s influence on clinical practice. Although there is some evidence in
support of the former claim,28, 29 it is unclear how those data generalize to the dissemination
of surgical research results. The latter assumption is untested and may have biased our
results.
Although we uncovered important results indicating the state of scientific rigor in surgical
trials, further study is warranted. The field would benefit from research into the most
effective means of educating surgical trialists and review board members in the use of bias-
reducing strategies in surgical research. Additional research into the best methods for
implementing methodological rigor in the testing of treatment modalities which appear
hostile to the most common bias reducing strategies would also be valuable.
Our results show that the methodological quality of surgical trials, as well as their reporting,
is in need of significant improvement. Clinical research ethics require that the risks of harm
to participants be outweighed by the value of the knowledge to be generated. The value and
clinical relevance of research-generated data is limited by both the internal and external
validity of findings. When trials are conducted without the use of adequate bias-reducing
techniques, participants are subjected to invasive procedures in order to produce findings of
questionable scientific value and generalizability to the medical community at large. The
ethical implications of these findings are compounded outside of the experimental setting,
Wenner et al. Page 5













when clinical interventionists treat patients with procedures which have not been proven
efficacious or safe.
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Review strategy and yield for trials of invasive therapeutic procedures for myocardial
infarction
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Review strategy and yield for trials of invasive therapeutic procedures overnutrition
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Table 1
Invasive Therapeutic Procedure Clinical Trial Search Strategy
Pubmed Search
   {MeSH Search Term}
    (randomized controlled trial [pt] OR controlled clinical trial [pt] OR comparative study [pt] OR evaluation studies [pt]) NOT (animal [mh]
NOT human [mh]) AND (surgical procedures [mh] OR surgi* [tw] OR surger* [tw] OR operativ* [tw] OR endosc* [tw] OR laser* [tw] OR
transplantation [mh] OR transpl* [tw])
   Limits
     Publication Date from January 1, 1999 to December 31, 2008
     Only items with Abstracts
     English
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Table 2
Medical Subject Headings (MeSH), number of publications 1999–2008 identified by the search strategy, and n















Aortic Aneurysm 1,466 113 (7.7) 9
Arrhythmia 2,100 181 (8.6) 7
Arthritis 1,701 171 (10.1) 15
Barrett Esophagus 300 18 (6.0) 7
Brain Neoplasm 1,423 15 (1.1) 5
Carcinoma, Bronchogenic & Non-Small-Cell-Lung 798 24 (3.0) 7
Carcinoma, Ductal, Breast 666 3 (0.5) 3
Carotid Artery Disease & Carotid Stenosis 1,016 76 (7.5) 13
Cerebrovascular Accident 2,584 302 (11.7) 8
Cholecystitis 225 32 (14.2) 5
Cholecystolithiasis 241 39 (16.2) 5
Colorectal Neoplasm 3,078 116 (3.8) 18
Coronary Disease 3,304 325 (9.8) 32
Dystonic Disorder 32 3 (9.4) 3
Embolism 875 72 (8.2) 7
Endometriosis 305 23 (7.5) 7
Esophageal Neoplasm 786 40 (5.1) 8
Esophagitis 501 33 (6.6) 7
Heart Failure, Congestive 2,571 125 (4.9) 6
Intracranial Arteriovenous Malformation 104 1 (1.0) 1
Laryngeal Neoplasm 396 19 (4.8) 6
Myocardial Infarction 3,819 395 (10.3) 13
Nephrolithiasis 188 23 (12.2) 12
Otitis Media 278 44 (15.8) 7
Ovarian Neoplasm 819 14 (1.7) 6
Overnutrition 1,066 72 (6.8) 6
Parkinson Disease & Parkinsonian Disorders 351 23 (6.6) 5
Peripheral Vascular Disease 823 75 (9.1) 10
Prostatic Hyperplasia 531 125 (23.5) 6
Prostatic Neoplasm 1,861 23 (1.2) 7
Pulmonary Disease, Chronic Obstructive 306 14 (4.6) 6
Thrombosis 2,556 186 (7.3) 10
Urinary Incontinence 874 134 (15.3) 23



























TOTALS 37,944 2,890 (7.6) 290
*
Total including eligible trial reports discovered by review of citation lists of meta-analyses
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Table 3




   Demonstrate superioritya 235/290 (81.0)
   Demonstrate equivalence or non-inferiority 43/290 (14.8)
   Assess safety 11/290 (3.8)
   Feasibility 1/290 (0.3)
Formal sample size and power calculation
   Not reported 106/290 (36.6)
   Reported 184/290 (63.4)
     Calculation included all elements 160/184 (87.0)
     Calculation allowed for dropouts and attrition 78/184 (42.4)
Primary endpoint
   Not reported 45/290 (15.5)
   Reported 245/290 (84.5)
     Composite primary endpoint 35/245 (14.3)
     Single objective primary endpointb 159/245 (64.9)
     Subjective primary endpoint 51/245 (20.8)
       Reported provenance of scale 24/51 (47.1)
       Reported validity 1/51 (2.0)
       Reported reliability 2/51 (3.9)
       Reported sensitivity 0/51 (0.0)
       Reported blinding of primary outcome assessor 20/51 (39.2)
Type of control group
   Concurrent 282/290 (97.2)
   Historical 8/290 (2.8)
Nature of comparator
   Placebo or sham procedure 11/290 (3.8)
   Alternative operative intervention 220/290 (75.9)
   Non-operative intervention 59/290 (20.3)
Allocation method
   Deterministicc 30/290 (10.3)
   Randomization 256/290 (88.3)
   Minimizationd 4/290 (1.4)
Allocation concealment (256 randomized trials only)
   Method described for generation of random allocation sequence 105/256 (41.0)
   Identification of person or entity generating the sequence 82/256 (32.0)
   Provided assurance that sequence was concealed until allocation 132/256 (51.6)

















   Trial reported some element of blinding 114/290 (39.3)
     Participants reported blinded 41/114 (36.0)
     Interventionist reported blinded 14/114 (12.4)
     Primary outcome assessors reported blinded 46/114 (40.4)
     Maintenance of blind reported assessed 5/114 (4.4)
Trial execution
   Participants receiving treatment as allocated
     Treatment received by allocation not reported 27/290 (9.3)
     <85% of intervention participants received intervention 13/263 (4.9)
     <85% of control participants received control condition 8/263 (3.0)
     Full crossover data not reported (256 randomized trials only) 29/256 (11.3)
     >10% crossovers, intervention to control 17/227 (7.5)
     >10% crossovers, control to intervention 9/227 (4.0)
   Follow-up
     Full data regarding completeness of follow-up not reported 41/290 (14.1)
     Reported follow-up in entire sample only 30/249 (12.0)
     <90% intervention participants completing follow-up 59/219 (26.9)
     <90% control participants completing follow-up 58/219 (26.5)
aOne trial was powered to show non-inferiority but the authors interpreted findings of “no significant difference” as supporting the claim that the
surgical procedure under investigation was superior on the grounds that surgery, in contrast to medical therapy, corrected the anatomic defect
thought to be responsible for the pathophysiology of the disease. We classified this trial as a superiority trial due to the ultimate claims made by the
authors.
bObjective endpoints were defined as those which were externally verifiable, i.e. re-admission or morbidity.
cOne trial was described as being randomized, but used hospital registration numbers for allocation (even to one group and odd to the other). This
trial was recorded as deterministic.
dOne trial began with a strategy of minimization, but switched to randomization midway. This trial was recorded as using minimization.
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Table 4
Attributes needed for assessing external validity or generalizability
Attribute N(%) Dossiers
N intervention centers
   N centers not reported 24/290 (8.3)
   Single center 133/266 (50.0)
   Multi-site 133/266 (50.0)
     Median number of centers (range) 12 (2–217)
     2–5 centers 40/133 (30.1)
     6–10 23/133 (17.3)
     >10 70/133 (52.6)
Eligibility criteria for inclusion of intervention centers (multi-center trials only)
   Not reported 117/133 (88.0)
   Inclusion criteria described 16/133 (12.0)
N surgeons/interventionists
   N interventionists not reported 225/290 (77.6)
   N interventionists reported 65/290 (22.4)
   Single interventionist 31/65 (47.7)
   Multiple interventionists 34/65 (52.3)
     Median number interventionists (range) 3.5 (2–66)
     2–5 interventionists 21/34 (61.8)
     6–10 7/34 (20.6)
     >10 6/34 (17.6)
Eligibility criteria for inclusion of interventionists (multi-interventionist trials only)
   Not reported 20/34 (58.8)
   Inclusion criteria described 14/34 (41.2)
Pre-trial standardization of operative technique (multi-interventionist trials only)
   Not reported 26/34 (76.5)
   Described critical elements of technique 8/34 (23.5)
Assessment of interventionist fidelity to standardized operative technique (multi-interventionist trials only)
   Not reported 31/34 (91.2)
   Assessment method described 3/34 (8.8)
Sponsor role in conduct of trial (Out of trials reporting commercial sponsorship only)
   Trial design 26/89 (29.2)
   Data analysis 31/89 (34.8)
   Preparation of manuscript 29/89 (32.6)
Size of trial
   Median number of trial participants (range) 121.5 (30–3,120)
   30 participants 4/290 (1.4)
   31–60 56/290 (19.3)
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Attribute N(%) Dossiers
   61–100 59/290 (20.3)
   101–200 63/290 (21.7)
   >200 108/290 (37.2)
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